Melanotan I, also known as afamelanotide, is a modified α-melanocyte-stimulating-hormone analogue associated with melanocortin and pigmentation research. Select your format and quantity for pricing, batch availability and lead time.
CAS
75921-69-6
Purity
>99%
Form
Lyophilized powder
Select a pack
1 option
Specification
10 mg / vial
Sales unit
box
Packaging
10 vials / box
Selected SKUMT1
Minimum listed format shown. Refer to the selected SKU specifications; final packaging is confirmed with your quotation.
Test method: HPLC. Catalogue specification. Confirm the supplied batch against its COA.
Price, batch and delivery terms confirmed with your quotation.
✓ Batch-linked records✓ Private-label support✓ Multiple formats✓ Research use only
ABOUT THE MATERIAL
Product overview
Identity, scientific context and the details that distinguish this entry.
Melanotan I, also known as afamelanotide, is a modified α-melanocyte-stimulating-hormone analogue associated with melanocortin and pigmentation research.[Sources]
The analogue is commonly designated [Nle4,D-Phe7]-α-MSH. Its linear peptide structure distinguishes it from cyclic Melanotan II.
Research variables
The paper investigates a specified implant and population. It provides molecular and melanocortin research context; formulation, release profile and route are properties of that study product.
A CLOSER LOOK
Mechanisms & published research
Read each finding with its study model and material identity.
01
A defined afamelanotide formulation in EPP
Two randomized trials evaluated a specified afamelanotide implant in erythropoietic protoporphyria. Measurements included pain-free sunlight exposure, phototoxic reactions and quality of life. These are disease- and formulation-specific endpoints that complement molecular melanocortin research.
Match the offered lot number, identity, test methods and reported results.
02
HPLC / MS records
Ask for available chromatograms and mass-identity records, including the method and reporting scope.
03
SDS & storage information
Confirm handling, transport and storage information for the offered material and packaging.
A document request adds no purchase quantity. Have a batch reference? Open batch records ↗
BEFORE YOU ENQUIRE
Common questions
Does the implant study describe this vial format?
The paper investigates a specified implant and population. It provides molecular and melanocortin research context; formulation, release profile and route are properties of that study product.
How should storage and handling be confirmed?
Use the specification and available safety or stability information for the offered lot, form and packaging. Request written conditions before ordering; literature alone does not establish a universal temperature, shelf life or reconstitution procedure.
How are catalogue specifications checked against a batch?
The displayed value is a catalogue specification. Assess the offered lot against its matching COA and method. Chromatographic purity, component content and biological activity are different measurements; confirm which results are available.
What information helps with a quotation?
Include the exact SKU, quantity in boxes, destination, desired timing and document requirements. State any label or packaging needs. Pricing, availability, lead time and document scope are confirmed in the quotation.
Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, Bloomer J, Edwards C, Neumann NJ, Parker C, Phillips JD, Lim HW, Hamzavi I, Deybach JC, Kauppinen R, Rhodes LE, Frank J, Murphy GM, Karstens FPJ, Sijbrands EJG, de Rooij FWM, Lebwohl M, Naik H, Goding CR, Wilson JHP, Desnick RJ. 2015, DOI: 10.1056/nejmoa1411481
Two randomized trials in erythropoietic protoporphyria
Publications describe their own study materials and methods. They are distinct from BatchTide specifications and lot-release records. Materials listed here are for laboratory research only, not for human or veterinary use.
EXPLORE THE CATALOGUE
Related research materials
Explore related entries. Similar research contexts do not establish interchangeability.